IRC
MRNA icon

Investors Research Corp’s Moderna MRNA Stock Holding History

Investors Research Corp’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.2K Hold
1,302
– – 0.02% 330
2026
Q1 		$66.1K Sell
1,302
-250
-16% -$11.7K 0.01% 370
2025
Q4 		$45.8K Sell
1,552
-925
-37% -$25.1K 0.01% 452
2025
Q3 		$64K Sell
2,477
-50
-2% -$1.4K 0.01% 420
2025
Q2 		$69.7K Hold
2,527
– – 0.01% 430
2025
Q1 		$71.6K Hold
2,527
– – 0.02% 415
2024
Q4 		$105K Hold
2,527
– – 0.02% 385
2024
Q3 		$169K Hold
2,527
– – 0.04% 327
2024
Q2 		$300K Hold
2,527
– – 0.07% 268
2024
Q1 		$269K Sell
2,527
-125
-5% -$12.6K 0.06% 282
2023
Q4 		$264K Hold
2,652
– – 0.06% 287
2023
Q3 		$274K Buy
2,652
+2,650
+132,500% +$296K 0.07% 278
2023
Q2 		$243 Hold
2
– – ﹤0.01% 1047
2023
Q1 		$307 Hold
2
– – ﹤0.01% 1076
2022
Q4 		$359 Hold
2
– – ﹤0.01% 1090
2022
Q3 		$0 Hold
2
– – ﹤0.01% 1118
2022
Q2 		$0 Hold
2
– – ﹤0.01% 1127
2022
Q1 		$0 Buy
+2
New +$337 ﹤0.01% 1071

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Investors Research Corp's MRNA Position: Q2 2026 in Review

Investors Research Corp held its Moderna (MRNA) position steady in Q2 2026 at 1,302 shares worth $91.2K. The position accounts for 0.02% of the portfolio, ranked #330.

Investors Research Corp first reported a position in MRNA in Q1 2022 and has held it in 18 quarters since. The position peaked at $300K in Q2 2024. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Investors Research Corp held 1,302 shares of Moderna worth $91.2K as of Q2 2026.
  • Investors Research Corp left its Moderna share count unchanged in Q2 2026.
  • Moderna made up 0.02% of Investors Research Corp's portfolio in Q2 2026, its #330 holding.
  • Investors Research Corp first reported a position in Moderna in Q1 2022 and has held it in 18 quarters since.
  • Investors Research Corp's Moderna position peaked at $300K in Q2 2024.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Investors Research Corp's 13F filing for Q2 2026, filed 10 Jul 2026.